KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Rui You, You-Ping Liu, Yu-Long Xie, Chao Lin, Chong-Yang Duan, Dong-Ping Chen, Yi Pan, Bin Qi, Xiong Zou, Ling Guo, Jing-Yu Cao, Yi-Nuan Zhang, Zhi-Qiang Wang, Yong-Long Liu, Yan-Feng Ouyang, Kai Wen, Qi Yang, Ruo-Qi Xie, Hui-Feng Li, Xiao-Tong Duan, Xi Ding, Lan Peng, Si-Yuan Chen, Jiong-Lin Liang, Zheng-Kai Feng, Tian-Liang Xia, Rui-Ling Xie, Rou Jiang, Chen-Mei Gu, Rong-Zeng Liu, Rui Sun, Xin Yang, Li-Zhi Liu, Li Ling, Qing Liu, Wai Tong Ng, Yi-Jun Hua, Pei-Yu Huang, Ming-Yuan Chen

Lancet 401(10380) 917-927

PMID36842439
PMCID-
DOI10.1016/S0140-6736(23)00269-6
发表日期2023-02-26
入排依据:The study is a Phase III randomized controlled trial for nasopharyngeal carcinoma with overall survival as a primary time-to-event endpoint. However, the intervention compares two radiotherapy fractionation schedules (hyperfractionated vs. standard fractionated intensity-modulated radiotherapy), which is a non-drug-only intervention. Drug intervention is not present or established.
摘要

摘要

BACKGROUND: Reirradiation in standard fractionation for locally advanced recurrent nasopharyngeal carcinoma after a previous course of high-dose radiotherapy is often associated with substantial late toxicity, negating its overall benefit. We therefore aimed to investigate the efficacy and safety of hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy. METHODS: This multicentre, randomised, open-label, phase 3 trial was done in three centres in Guangzhou, China. Eligible patients were aged 18-65 years with histopathologically confirmed undifferentiated or differentiated, non-keratinising, advanced locally recurrent nasopharyngeal carcinoma. Participants were randomly assigned (1:1) to either receive hyperfractionation (65 Gy in 54 fractions, given twice daily with an interfractional time interval of at least 6 h) or standard fractionation (60 Gy in 27 fractions, given once a day). Intensity-modulated radiotherapy was used in both groups. A computer program generated the assignment sequence and randomisation was stratified by treatment centre, recurrent tumour stage (T2-T3 vs T4), and recurrent nodal stage (N0 vs N1-N2), determined at the time of randomisation. The two primary endpoints were the incidence of severe late complications defined as the incidence of grade 3 or worse late radiation-induced complications occurring 3 months after the completion of radiotherapy until the latest follow-up in the safety population, and overall survival defined as the time interval from randomisation to death due to any cause in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02456506. FINDINGS: Between July 10, 2015, and Dec 23, 2019, 178 patients were screened for eligibility, 144 of whom were enrolled and randomly assigned to hyperfractionation or standard fractionation (n=72 in each group). 35 (24%) participants were women and 109 (76%) were men. After a median follow-up of 45·0 months (IQR 37·3-53·3), there was a significantly lower incidence of grade 3 or worse late radiation-induced toxicity in the hyperfractionation group (23 [34%] of 68 patients) versus the standard fractionation group (39 [57%] of 68 patients; between-group difference -23% [95% CI -39 to -7]; p=0·023). Patients in the hyperfractionation group had better 3-year overall survival than those in the standard fractionation group (74·6% [95% CI 64·4 to 84·8] vs 55·0% [43·4 to 66·6]; hazard ratio for death 0·54 [95% CI 0·33 to 0·88]; p=0·014). There were fewer grade 5 late complications in the hyperfractionation group (five [7%] nasal haemorrhage) than in the standard fractionation group (16 [24%], including two [3%] nasopharyngeal necrosis, 11 [16%] nasal haemorrhage, and three [4%] temporal lobe necrosis). INTERPRETATION: Hyperfractionated intensity-modulated radiotherapy could significantly decrease the rate of severe late complications and improve overall survival among patients with locally advanced recurrent nasopharyngeal carcinoma. Our findings suggest that hyperfractionated intensity-modulated radiotherapy could be used as the standard of care for these patients. FUNDING: Key-Area Research and Development of Guangdong Province, the National Natural Science Foundation of China, the Special Support Program for High-level Talents in Sun Yat-sen University Cancer Center, the Guangzhou Science and Technology Plan Project, and the National Ten Thousand Talents Program Science and Technology Innovation Leading Talents, Sun Yat-Sen University Clinical Research 5010 Program.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。